CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...
Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...
CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...
If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...
Vertex Pharmaceuticals, best known for its breakthrough cystic fibrosis (CF) treatments, is to become one of the first partners of CRISPR Therapeutics, a leader in new gene-editing technology.
瑞士楚格和波士顿 - 目前股价为$39.69,市值33.9亿美元的CRISPR Therapeutics (NASDAQ:CRSP)宣布了其2025年战略重点,专注于继续推出其基因药物CASGEVY®以及几个关键开发项目的更新。公司以强劲的资产负债表开始新的一年,拥有约19亿美元的现金、现金等价物和可销售证券。